Princeton based Sonnet Biotherapeutics [NASDAQ:SONN] has an interesting “Trojan Horse” approach that appears to have considerable promise with application in Covid – 19. Sonnet has developed a unique platform that leverages several favorable biological properties of human serum Albumin. They have invented and developed an ingenious approach that converts endogenous albumin into a drug-loaded and/or immune stimulatory Trojan Horse that is taken up by unknowing cancer cells, leading to their destruction”. To see the full Report visit the Research Reports tab or this link.
Author: Brett Johnson
By learning from a MERS outbreak in 2015, South Korea was prepared and acted swiftly to ramp up testing when the new coronavirus appeared there. Meanwhile, the U.S., plagued by delay and dysfunction, wasted its advantage. In the aftermath of a 2015 outbreak of the Middle East Respiratory Syndrome that killed 38 people and cratered the economy, South Korea took a hard look at what had gone wrong. Korean officials enacted a key reform, allowing the government to give near-instantaneous approval to testing systems in an emergency. Within weeks of the current outbreak in Wuhan, China, four Korean companies had…
Samsung Biologics and Vir Biotechnology, Inc announced April 9th a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir’s SARS-CoV-2 monoclonal antibody (mAb) program. “Vir’s candidate molecules supported by Samsung Biologics’ production scale have the potential to bring hope to countless lives across nations suffering from COVID-19.” said Dr. Tae Han Kim, CEO of Samsung Biologics. Vir’s lead SARS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly into a phase 2 clinical trial…
Long-term protection to this virus comes from antibodies, small proteins produced by your immune system that attack the virus and neutralise it so it cannot be spread and cannot do any more damage to the person infected. These antibodies emerge during an infection and peak 28 days after the infection. They then remain for months afterwards continuing to provide protection, and the cells that produce them also are available to fight off the infection if it returns. These antibodies see anything foreign (like a virus) and bind to many different parts of the virus. Some antibodies are better than others…
Cepheid has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its rapid molecular diagnostic test, Xpert Xpress SARS-CoV-2. The test is designed for the qualitative detection of SARS-CoV-2 virus, which causes coronavirus (Covid-19) disease. Designed to operate on the company’s automated GeneXpert Systems, it has a detection time of approximately 45 minutes. Cepheid chief medical and technology officer Dr David Persing said: “By leveraging the design principles of our current Xpert Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and potential future…
Co-Diagnostics offers a range of products and services to suit the needs of diagnostics laboratories, research institutions, and enterprises across the globe that rely on PCR technology. Co-Diagnostics was founded with a simple but ambitious goal: to bring high-quality molecular diagnostics for infectious diseases to areas and populations of the world that need them most. Since that time, Co-Diagnostics researchers have developed additional applications far beyond the detection of infectious diseases.
Discussion of Trump’s comments regarding withholding funds from the WHO (World Health Organization) because of its failure to manage China. USA contributes about 118 million each year to WHO. China about 40 million.
The Food and Drug Administration on Thursday authorized its first emergency use coronavirus serology test. The test was developed by Cellex Inc. and involves a blood draw done at a certified lab. It can provide results in 15 minutes. FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19,” FDA chief scientist Denise M. Hinton said, adding “The known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product.” The test will determine whether an individual has developed antibodies to the virus, which would be…